We are live on ! Find out more
SGYP

Synergy Pharmaceuticals, Inc Common Stock
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

128 hedge funds and large institutions have $175M invested in Synergy Pharmaceuticals, Inc Common Stock in 2016 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 33 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

238% more call options, than puts

Call options by funds: $4.95M | Put options by funds: $1.46M

24% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 33

4% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 23

1% more funds holding

Funds holding: 127128 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

51% less capital invested

Capital invested by funds: $360M → $175M (-$185M)

Holders
128
Holders Change
+1
Holders Change %
+0.79%
% of All Funds
3.41%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
24
Increased
41
Reduced
33
Closed
23
Calls
$4.95M
Puts
$1.46M
Net Calls
+$3.48M
Net Calls Change
+$1.29M
Name Holding Trade Value Shares
Change
Change in
Stake
PC
1
Paulson & Co
New York
$30.6M +$7.57M +2,090,000 +23%
Vanguard Group
2
Vanguard Group
Pennsylvania
$18.8M +$804K +221,924 +3%
BFA
3
BlackRock Fund Advisors
California
$15.7M +$1.42M +392,916 +7%
State Street
4
State Street
Massachusetts
$10.1M -$540K -149,076 -4%
BIT
5
BlackRock Institutional Trust
California
$7.16M +$32K +8,835 +0.3%
O
6
OrbiMed
New York
$6.28M
AC
7
Armistice Capital
New York
$6.07M +$7.97M +2,200,000 New
GPP
8
Great Point Partners
Connecticut
$6M +$2.27M +628,112 +41%
Invesco
9
Invesco
Georgia
$5.88M
Franklin Resources
10
Franklin Resources
California
$5.62M
Millennium Management
11
Millennium Management
New York
$4.91M -$3.48M -961,319 -35%
TS
12
Twin Securities
New York
$4.66M +$874K +241,383 +17%
JP Morgan Chase
13
JP Morgan Chase
New York
$3.6M +$1.02M +281,991 +28%
SG Americas Securities
14
SG Americas Securities
New York
$3.5M +$4.59M +1,267,412 New
Northern Trust
15
Northern Trust
Illinois
$3.07M -$27.8K -7,664 -0.7%
LCM
16
Landscape Capital Management
New Jersey
$2.76M +$3.42M +944,254 +1,694%
HighTower Advisors
17
HighTower Advisors
Illinois
$2.37M +$2.59M +714,615 +493%
FHAM
18
Folger Hill Asset Management
New York
$2.21M +$2.9M +800,000 New
Citigroup
19
Citigroup
New York
$1.75M -$787K -217,280 -26%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$1.74M -$769K -212,420 -25%
Deutsche Bank
21
Deutsche Bank
Germany
$1.72M -$349K -96,406 -13%
PVI
22
Pura Vida Investments
New York
$1.58M +$724K +200,000 +54%
Goldman Sachs
23
Goldman Sachs
New York
$1.54M +$797K +220,145 +65%
Citadel Advisors
24
Citadel Advisors
Florida
$1.53M -$7.03M -1,940,620 -78%
GCM
25
Gruss Capital Management
New York
$1.38M +$1.81M +500,000 New

SGYP Hedge Fund Activity: Q1 2016 in Review

128 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q1 2016, worth a combined $175M — down 51% from $360M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SGYP positions and 23 closed out — a net gain of 1 holder — while 41 added to existing stakes and 33 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $7.97M. The largest seller was Citadel Advisors, cutting an estimated $7.03M.

  • 128 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q1 2016, up from 127 in Q4 2015.
  • Funds reported $175M of Synergy Pharmaceuticals, Inc Common Stock stock for Q1 2016, down 51% quarter-over-quarter.
  • 24 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q1 2016 and 23 closed out, a net change of +1 holder.
  • The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q1 2016 was Armistice Capital, an estimated $7.97M added.
  • The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q1 2016 was Citadel Advisors, an estimated $7.03M sold.

Based on aggregated 13F filings for Q1 2016.